Can you still get compounded semaglutide or tirzepatide after FDA’s proposal?

Short answer: yes, some people may still be able to get a compounded semaglutide or tirzepatide product in limited situations, but FDA‘s April 30, 2026 action made the path narrower and more uncertain.

Just as important, the April 30 action was a proposal, not a same-day nationwide ban on every compounded GLP-1 refill. It focused on one federal route used by large outsourcing facilities, called 503B. That distinction matters if you are trying to figure out whether your next refill is still available.

What FDA proposed on April 30, 2026

On April 30, 2026, FDA said it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list because it did not find a clinical need for outsourcing facilities to compound those drugs from bulk drug substances. The public comment period runs through June 29, 2026, and FDA has not yet issued a final decision.

In plain English, FDA is proposing to shut off a bulk-compounding route used by large facilities that make compounded drugs at scale. It does not mean every compounded GLP-1 prescription everywhere in the United States became illegal on April 30.

What 503B means in plain language

503B facilities are outsourcing facilities that can compound certain drugs in larger quantities. FDA says these facilities generally cannot use a bulk drug substance unless one of two things is true: the ingredient is on the 503B bulks list, or the compounded drug is on FDA’s drug shortage list at the time of compounding, distribution, and dispensing.

That is why the April 30 proposal matters. If semaglutide and tirzepatide are not on the shortage list and also are not permitted through the 503B bulks pathway, that removes the main bulk-compounding route for many large-scale compounded GLP-1 products.

What 503A means in plain language

A different pathway, called 503A, applies to state-licensed pharmacies and physicians compounding for an individual patient based on a prescription. But that route has limits too. FDA says 503A compounders generally should not make products that are essentially copies of commercially available approved drugs.

There is an important exception: a prescriber can document that a change in the compounded product creates a significant difference for a specific patient. That means some narrow patient-specific compounding may still happen. But patients should not assume that their usual compounded refill automatically qualifies just because they have been receiving it.

Why access had already tightened before the April 30 proposal

For many patients, compounded access had already started shrinking well before April 30, 2026.

FDA said the tirzepatide injection shortage was resolved on December 19, 2024. It later said the semaglutide injection shortage was resolved on February 21, 2025. On April 1, 2026, FDA reminded compounders that tirzepatide and semaglutide did not currently appear on either the 503B bulks list or the FDA drug shortage list.

That timeline matters because some earlier flexibility depended on shortage status. Once those shortage-based windows closed, compounders faced the usual copy restrictions again.

What patients may still be able to get

Some patients may still obtain a compounded product through a patient-specific 503A pathway if the legal conditions are met and the prescriber documents why the compounded version is meaningfully different for that individual. But that is not the same thing as broad routine availability.

If your pharmacy has been filling a compounded GLP-1 for months, it is reasonable to ask which pathway it is relying on now. A refill that was available during a shortage period may not fit the same rules today.

It is also important to separate access from FDA’s clinical-need standard. In the underlying Federal Register notice, FDA says supply issues such as backorders, plus convenience or lower cost, are not the same as clinical need for adding a bulk substance to the 503B list. That does not make cost and access unimportant to patients. It does explain why those arguments alone may not keep a bulk-compounding pathway open under this rule.

FDA’s safety concerns with compounded GLP-1 products

FDA has repeatedly warned about risks tied to unapproved compounded GLP-1 products. These compounded versions are not FDA-approved drugs, and the agency says it has received reports of dosing errors, including cases that required hospitalization. Some problems involved patients measuring the wrong dose. Others involved doses or titration schedules that went beyond the FDA-approved labeling.

FDA also says some injectable compounded GLP-1 products have arrived warm or without enough refrigeration during shipping, which can affect quality. The agency has warned about fraudulent labels, including products that named pharmacies that did not actually make them. It has also said some compounders used semaglutide salt forms, such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the one used in approved drugs and do not have a lawful basis for compounding under the agency’s view.

FDA further warns that illegally marketed online products may be counterfeit, may contain the wrong ingredients, or may contain too little, too much, or no active ingredient at all.

Do not stop treatment on your own

If you use semaglutide or tirzepatide, do not stop treatment abruptly just because a refill situation suddenly changed. MedlinePlus says people should not stop semaglutide or tirzepatide without talking to their clinician.

That is especially important if you are using one of these medicines for diabetes, weight management, or another FDA-approved indication. A treatment interruption can affect blood sugar, appetite, side effects, and how a future restart is handled. Your clinician or pharmacist may be able to discuss approved alternatives, dose transitions, or coverage options, but those details vary by product, plan, and local supply.

What readers can do before the next refill

Ask the pharmacy which compounding pathway applies to your prescription now: 503A patient-specific compounding or something else.
Ask whether your prescriber documented a significant difference for you if the product is being made as a patient-specific compounded copy.
Confirm the source and storage of the medicine. If an injectable product arrives warm, damaged, or with suspicious labeling, contact the pharmacy before using it.
Check that the pharmacy is state-licensed and that the prescription came from a licensed clinician.
Do not buy semaglutide or tirzepatide from websites marketing products for research use or from sellers that cannot clearly identify the pharmacy.
If your refill is delayed, contact your prescriber early rather than waiting until you are out of medication.

When to get medical help

Call your clinician promptly if you have severe nausea or vomiting, trouble staying hydrated, new injection-site problems, or questions about a dose you already took.

Seek urgent or emergency care for symptoms such as severe stomach pain that may spread to the back, trouble breathing, swelling of the face or throat, fainting, or signs of a serious allergic reaction.

What is still not known

FDA has not made a final decision on the April 30, 2026 proposal. The comment period stays open through June 29, 2026, and the final agency action could affect future access differently than the proposal alone.

It is also not possible to answer every refill question with one national rule of thumb. A patient’s diagnosis, the exact product, the pharmacy’s license status, the prescriber’s documentation, insurer rules, and local availability can all change what happens next.

For now, the safest bottom line is this: FDA’s April 30 proposal did not instantly end every compounded semaglutide or tirzepatide refill in the United States, but it did signal that routine bulk compounding through 503B facilities is under increasing pressure. If you rely on one of these medicines, now is the time to verify your refill pathway instead of assuming it will continue unchanged.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.